Use of ox40 and ox40l modulators to treat hidradenitis suppurativa
By targeting the OX40L/OX40 pathway with OX40 modulators, the treatment of hidradenitis suppurativa addresses the inadequacies of current therapies, improving clinical scores and quality of life for HS patients by reducing OX40 expression levels.
Patent Information
- Application Number
- PCT/EP2024/067352
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-09
- Filing Date
- 2024-06-20
- Publication Date
- 2024-12-26
AI Technical Summary
Current treatments for hidradenitis suppurativa (HS) are inadequate, with moderate-to-severe patients often experiencing insufficient control and significant psychological distress due to the lack of effective therapies, and existing biologics like Humira show declining efficacy over time, leading to poor prognosis and quality of life impairment.
Targeting the OX40L/OX40 signaling pathway by administering OX40 modulators or anti-OX40 ligand (OX40L) modulators to reduce OX40 expression levels, which are found to be upregulated in HS patients, thereby improving clinical scores and treatment outcomes.
The use of OX40 modulators demonstrates potential in improving Dermatology Life Quality Index, International HS Severity Score System, and Hurley Classification scores, offering a novel therapeutic approach for HS, with reduced OX40 expression levels correlating with treatment efficacy.
Smart Images

Figure EP2024067352_26122024_PF_FP_ABST
Abstract
Description
[0001] USE OF 0X40 AND OX40L MODULATORS TO TREAT HIDRADENITIS SUPPURATIVA
[0002] RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application Nos. 63 / 522,079 filed June 20, 2023, and 63 / 551,901 filed February 9, 2024, each of which is incorporated by reference herein in its entirety.
[0004] BACKGROUND
[0005] Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease marked by recurrent, painful, deep-seated, nodules and abscesses of apocrine gland-bearing skin. The age of onset peaks at approximately 20 to 40 years of age, with females more affected than males. HS is a chronic, relapsing, debilitating, inflammatory skin disease that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine glandbearing areas of the body, most commonly the axillary, inguinal, and anogenital regions (Dessau definition, 1st International Conference on Hidradenitis Suppurativa, 30 March 2006 to 01 April 2006, Dessau, Germany) (Fimmel et al. (2010) Dermatoendocrinol. 2(1):9-16; Kurzen et al. (2008) Expl. Dermatol. 17(5):455-6; discussion:457-72). HS is progressive, with initial obstructed hair follicles and secondary infection forming inflamed clusters with lasting deformity and severe psychological distress. The cause of initial obstruction and inflammation is unknown.
[0006] HS affects greater than 300,000 diagnosed patients in the US, over half of whom are moderate-severe, with a diminished quality of life (QoL). Their needs remain unmet by the lack of efficacious treatments. Moderate-to-severe HS patients are often insufficiently controlled by topical antibiotics and intralesional corticosteroids, requiring Humira treatment, the only approved biologic approved in the U.S. for HS.
[0007] If left untreated, prognosis is poor for severe disease, with potential need for wide excision, grafting, and / or gland removal. HS patients can be segmented into mild, moderate, and severe designations based on the widely-accepted Hurley Classification. Severity of HS is defined by the nature of abscesses: number; distribution (e.g., armpit, chest, groin); sinus tract involvement; and cicatrization. HS has no impact on mortality; however it has high morbidity due to painful lesions, drainage, and scarring that can result in social isolation and psychological distress. Despite Humira use, widespread dissatisfaction has been reported, with lacking efficacy and durability, noting subsequent decrease in response rates over time. Although Cosentyx, Stelara, and other compounds may be used off-label in a refractory population, coverage for these compounds can be a barrier to access.
[0008] SUMMARY
[0009] The present disclosure is based on the discovery that the OX40L / OX40 signaling pathway is upregulated in hidradenitis suppurativa (HS) compared to a control sample, and can be a novel therapeutic target to treat HS.
[0010] In one aspect, a method of treating HS in a subject in need thereof is provided, comprising administering to the subject an effective amount of an 0X40 modulator or an anti-OX40 ligand (OX40L) modulator.
[0011] In certain exemplary embodiments, one or more of Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), and Hurley Classification scores are improved in the subject.
[0012] In certain exemplary embodiments, 0X40 expression level is reduced in the subject.
[0013] In another aspect, a method of treating HS in a subject in need thereof is provided, comprising selecting a subject having an increased expression level of 0X40 relative to a control, and administering to the subject an effective amount of an 0X40 modulator or an anti-OX40 ligand (OX40L) modulator.
[0014] In another aspect, a method of diagnosing or detecting hidradenitis suppurativa (HS) in a subject is provided, the method comprising or consisting of the steps of: a) providing a sample obtained from a subject to be tested; and b) measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L), wherein the presence and / or amount in the sample of 0X40 and / or OX40L is indicative of HS in the subject.
[0015] In a further aspect, a method of selecting a subject having hidradenitis suppurativa (HS) for treatment is provided, the method comprising or consisting of the steps of: a) providing a sample obtained from a subject to be tested; and b) measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L), wherein the subject is selected as suitable for treatment based on the measurement in step b). In another aspect, a method of assessing the efficacy of a treatment regimen for treating hidradenitis suppurativa (HS) in a subject is provided, the method comprising or consisting of the steps of: a) providing a treatment sample obtained from a subject following administration of a treatment regimen for HS; and b) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L).
[0016] In an additional aspect, the use of one or more agents able to detect 0X40 and / or 0X40 ligand (OX40L) for diagnosing or detecting hidradenitis suppurativa (HS) in a subject is provided.
[0017] BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate exemplary embodiments of the disclosure, and, together with the general description given above and the detailed description given below, serve to explain the features of the disclosure.
[0019] FIG. 1 depicts that the 0X40 pathway is significantly enriched in dysregulated genes of HS.
[0020] FIG. 2 depicts that 0X40 (TNFRSF4) expression level is higher in HS tissue relative to normal tissue.
[0021] FIG. 3 depicts 0X40 expression data.
[0022] FIG. 4 depicts 0X40 expression in CD4 T cells of the skin from HS patients.
[0023] FIG. 5 depicts that an anti-OX40L treated downregulated gene signature showed significant overlap with upregulated genes in HS.
[0024] FIG. 6 depicts the OX40L profiles used in Example 1.
[0025] FIG. 7 depicts OX40L expression levels in healthy skin and HS skin samples. Mann-Whitney test. **: p-value = 0.0011; ***: p-value < 0.001; ****: p < 0.0001.
[0026] FIG. 8 depicts 0X40 expression levels in healthy skin and HS skin samples. Mann- Whitney test. **: p-value = 0.0011; ***: p-value < 0.001; ****: p < 0.0001.
[0027] FIG. 9 depicts 0X40+ and OX40L+ cell densities in healthy skin and HS skin. Mann-Whitney test. ****: p-value<0.0001.
[0028] DETAILED DESCRIPTION Embodiments of the present disclosure provide 0X40 AND OX40L modulators for methods of treating or preventing hi dradenitis suppurativa (HS) in a subject in need thereof. Also provided as aspects of the invention are specific methods for diagnosing or detecting HS, methods for selecting a subject with HS for treatment, and methods for assessing efficacy of a treatment regimen and the use of one or more binding agents able to detect 0X40 and / or OX40L for diagnosing or detecting HS in a subject. It will be appreciated by persons skilled in the art that the descriptions and options relating to any one of these aspects of the invention may also apply for the other aspects of the present invention, as they are related methods and uses.
[0029] In one aspect, a method of treating HS in a subject in need thereof is provided, comprising administering to the subject an effective amount of an 0X40 modulator or an anti-OX40 ligand (OX40L) modulator.
[0030] According to certain aspects, the present invention includes methods of treating HS and / or methods of improving an HS-associated parameter in a subject by administering to the subject an effective amount of an 0X40 modulator or an 0X40 ligand (OX40L) modulator. Examples of “HS-associated parameters” include Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), Hurley Classification scores 0X40 expression and OX40L expression.
[0031] In certain exemplary embodiments, one or more of Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), and Hurley Classification scores are improved in the subject. Thus, in certain exemplary embodiments, one or more of Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), and Hurley Classification scores are improved in the subject following administration of an 0X40 modulator or an OX40L modulator.
[0032] By an “improvement in a HS-associated parameter” we include the meaning of a decrease from baseline of one or more of DLQI, IHS4, Hurley Classification scores, 0X40 expression levels and OX40L expression levels. By “baseline,” in relation to an HS- associated parameter, we include the meaning of the numerical value of the HS-associated parameter for a subject prior to or at the time of administration of a 0X40 modulator or the OX40L modulator.
[0033] To determine whether a HS-associated parameter has “improved,” the parameter is quantified at baseline and at one or more time points after administration of a 0X40 modulator and / or a OX40L modulator. For example, an HS-associated parameter may be measured at day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 14, day 15, day 22, day 25, day 29, day 36, day 43, day 50, day 57, day 64, day 71, day 85; or at the end of week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12, week 13, week 14, week 15, week 16, week 17, week 18, week 19, week 20, week 21, week 22, week 23, week 24, or longer, after the initial treatment with a 0X40 modulator and / or the OX40L modulator. The difference between the value of the parameter at a particular time point following initiation of treatment and the value of the parameter at baseline is used to establish whether there has been an “improvement” (e.g., a decrease) in the HS-associated parameter.
[0034] In certain exemplary embodiments, 0X40 and / or OX40L expression level is reduced in the subject. Thus, in certain exemplary embodiments, 0X40 and / or OX40L expression level is reduced in the subject following administration of an 0X40 modulator or an OX40L modulator. Methods for assessing 0X40 and / or OX40L expression level are known in the art and described herein,
[0035] To determine whether 0X40 and / or OX40L expression level is “reduced” in the subject, the parameter is quantified at baseline and at one or more time points after administration of a 0X40 modulator or a OX40L modulator. For example, 0X40 and / or OX40L expression level may be measured at day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 14, day 15, day 22, day 25, day 29, day 36, day 43, day 50, day 57, day 64, day 71, day 85; or at the end of week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12, week 13, week 14, week 15, week 16, week 17, week 18, week 19, week 20, week 21, week 22, week 23, week 24, or longer, after the initial treatment with a 0X40 modulator or the OX40L modulator. The difference between the value of the parameter at a particular time point following initiation of treatment and the value of the parameter at baseline is used to establish whether there has been a reduction in 0X40 and / or OX40L expression.
[0036] As used herein, “a subject in need thereof’ may include, e.g., subjects who, prior to treatment, exhibit (or have exhibited) one or more HS-associated parameters such as those described herein.
[0037] As used herein, by “expression level” we include the meaning of the presence and / or amount of 0X40 and / or OX40L in a biological sample provided from a subject. As discussed herein, the expression level of 0X40 and / or OX40L in the subject's sample can be compared to the expression level of 0X40 and / or OX40L in a sample from a control subject.
[0038] As exemplified in the accompanying Examples, the expression of 0X40 and / or OX40L in a biological test sample may be indicative of HS in a subject. For example, the relative expression of 0X40 and / or OX40L in a single test sample may be indicative of the presence of HS in a subject. In an embodiment, the biological test sample is a tissue sample, a whole blood sample, a urine sample, a saliva sample, a serum sample, a plasma sample or a fecal sample.
[0039] In further embodiments, the sample may be a fresh, frozen or preserved sample or a fine needle aspirate. In particular embodiments, the sample is a formalin-fixed, paraffin- embedded (FFPE) sample.
[0040] In an embodiment, the biological test sample is a tissue sample, such as a skin sample.
[0041] In an alternative or additional embodiment, the expression level in the test sample may be compared against a reference value or a control sample, such as a negative control sample. In an embodiment, the negative control sample is a biological sample of the same type as the test sample, taken from an individual who was not, at the time the sample was obtained, afflicted with HS. Thus, the negative control sample may be obtained from a healthy individual. The reference value may be the “typical” value for that parameter in a healthy subject (i.e. a negative reference value). Alternatively, the reference value may be a value for that parameter in a subject suffering from HS (i.e. a positive reference value).
[0042] A wide variety of 0X40 and / or OX40L modulators can be used in the methods of the present invention, such as antibodies, fusion proteins, adnectins, aptamers, anticalins, lipocalins, nucleic acids (e.g., antisense molecules, such as RNA interfering agents and ribozymes), inumunoconjugates (e.g., an antibody conjugated to a therapeutic agent), small molecules, fusion proteins, 0X40 and / or OX40L-derived peptidic compounds, and receptor-based antagonists.
[0043] In any aspect or example herein, the 0X40 can be human 0X40 (hOX40). In any aspect or example herein, the OX40L can be human OX40L (hOX40L).
[0044] In an embodiment of any aspect of the invention, the 0X40 modulator is an 0X40 antagonistic antibody. In an embodiment of any aspect of the invention, the OX40L modulator is an OX40L antagonistic antibody. 0X40 and / or OX40L antagonistic antibodies used in the methods of the present invention can be administered via any suitable method including, but not limited to subcutaneous administration, intravenous, or intramuscular.
[0045] In another aspect, a method of treating HS in a subject in need thereof is provided, comprising selecting a subject having an increased expression level of 0X40 relative to a control, and administering to the subject an effective amount of an 0X40 modulator or an anti-OX40 ligand (OX40L) modulator.
[0046] In another aspect, a method of diagnosing or detecting hidradenitis suppurativa (HS) in a subject is provided, the method comprising or consisting of the steps of: a) providing a sample obtained from a subject to be tested; and b) measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L), wherein the presence and / or amount in the sample of 0X40 and / or OX40L is indicative of HS in the subject.
[0047] In an embodiment, the method further comprises or consists of the steps of: c) providing one or more control samples; and d) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L), measured in step (b); wherein the subject is identified as having HS by comparing the presence and / or amount in the test sample of the 0X40 and / or 0X40 ligand (OX40L) in step (b) with the presence and / or amount in the control samples.
[0048] Optionally the control samples of step (c) are provided from a subject not having HS (negative control). Optionally, the subject not having HS is a healthy individual (negative control). Alternatively, or additionally, the control samples of step (c) are provided from a subject with HS (positive control).
[0049] Thus, the subject may be identified as having HS in the event that the presence and / or amount in the test sample of 0X40 and / or OX40L measured in step (b) is different from the presence and / or amount in the control sample. Alternatively, the presence and / or amount in the test sample of 0X40 and / or OX40L measured in step (b) corresponds to the presence and / or amount in the control sample of 0X40 and / or OX40L measured in step (d), i.e. the control sample is a positive control.
[0050] In another aspect, a method of selecting a subject having hidradenitis suppurativa (HS) for treatment is provided, the method comprising or consisting of the steps of: a) providing a sample obtained from a subject to be tested; and b) measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L), wherein the subject is selected as suitable for treatment based on the measurement in step b). In an embodiment, the method further comprises or consists of the steps of: c) providing one or more control samples; and d) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L), measured in step (b); wherein the subject is selected for treatment by comparing the presence and / or amount in the test sample of the 0X40 and / or 0X40 ligand (OX40L) in step (b) with the presence and / or amount in the control samples.
[0051] In an embodiment, the treatment comprises the standard of care for HS and / or administration of an 0X40 modulator or an OX40L modulator.
[0052] In an embodiment, the control samples of step (c) are provided from a healthy individual (negative control) and / or from an individual with HS (positive control).
[0053] Optionally the control samples of step (c) are provided from a subject not having HS (negative control). Optionally, the subject not having HS is a healthy individual (negative control). Alternatively, or additionally, the control samples of step (c) are provided from a subject with HS (positive control).
[0054] Thus, the subject may be selected for treatment in the event that the presence and / or amount in the test sample of 0X40 and / or OX40L measured in step (b) is different from the presence and / or amount in the control sample. Alternatively, the presence and / or amount in the test sample of 0X40 and / or OX40L measured in step (b) corresponds to the presence and / or amount in the control sample of 0X40 and / or OX40L measured in step (d), i.e. the control sample is a positive control.
[0055] Where multiple control samples are provided, they may be of the same type (e.g., all skin samples) or of different types (e.g., serum and skin samples). In an embodiment, the test sample types and control sample types are matched / corresponding. For example, if the sample from the subject being tested is a skin sample (e.g., a cell, a collection of cells, or tissue obtained from skin), then the negative control sample can also be a skin sample from a subject not suffering from HS.
[0056] By “is different to the presence and / or amount in a control sample” we mean or include the presence and / or amount of 0X40 and / or OX40L in the test sample differs from that of the one or more control sample (or to predefined reference values representing the same). In an embodiment, the presence and / or amount in the test sample differs from the presence or amount in the one or more control sample (or mean of the control samples) by at least ±5%, for example, at least ±6%, ±7%, ±8%, ±9%, ±10%, ±11%, ±12%, ±13%, ±14%, ±15%, ±16%, ±17%, ±18%, ±19%, ±20%, ±21%, ±22%, ±23%, ±24%, ±25%, ±26%, ±27%, ±28%, ±29%, ±30%, ±31%, ±32%, ±33%, ±34%, ±35%, ±36%, ±37%, ±38%, ±39%, ±40%, ±41%, ±42%, ±43%, ±44%, ±45%, ±41%, ±42%, ±43%, ±44%, ±55%, ±60%, ±65%, 35 ±66%, ±67%, ±68%, ±69%, ±70%, ±71%, ±72%, ±73%, ±74%, ±75%, ±76%, ±77%, ±78%, ±79%, ±80%, ±81%, ±82%, ±83%, ±84%, ±85%, ±86%, ±87%, ±88%, ±89%, ±90%, ±91%, ±92%, ±93%, ±94%, ±95%, ±96%, ±97%, ±98%, ±99%, ±100%, ±125%, ±150%, ±175%, ±200%, ±225%, ±250%, ±275%, ±300%, ±350%, ±400%, ±500% or at least ±1000% of the one or more control sample (e.g., the negative control sample).
[0057] Alternatively or additionally, the presence or amount in the test sample differs from the mean presence or amount in the control samples by at least >1 standard deviation from the mean presence or amount in the control samples, for example, >1.5, >2, >3, >4, >5, >6, >7, >8, >9, >10, >11, >12, >13, >14 or >15 standard deviations from the from the mean presence or amount in the control samples. Any suitable means may be used for determining standard deviation (e.g., direct, sum of square, Welford’s), however, in one embodiment, standard deviation is determined using the direct method (i.e., the square root of [the sum the squares of the samples minus the mean, divided by the number of samples]).
[0058] Alternatively or additionally, by “is different to the presence and / or amount in a control sample” we mean or include that the presence or amount in the test sample does not correlate with the amount in the control sample in a statistically significant manner. By “does not correlate with the amount in the control sample in a statistically significant manner” we mean or include that the presence or amount in the test sample correlates with that of the control sample with a p-value of >0.001, for example, >0.002, >0.003, >0.004, >0.005, >0.01, >0.02, >0.03, >0.04 >0.05, >0.06, >0.07, >0.08, >0.09 or >0.1. Any suitable means for determining p-value known to the skilled person can be used, including z-test, t-test, Student's t-test, f-test, Mann- Whitney U test, Wilcoxon signed-rank test and Pearson's chi-squared test.
[0059] Alternatively, as described above, HS may be identified in the event that the presence and / or amount in the test sample of 0X40 and / or OX40L measured in step (b) corresponds to the presence and / or amount in the control sample of 0X40 and / or OX40L measured in step (d) ), i.e. the control sample is a positive control. Thus, the methods of the invention may comprise steps (c) + (d) for either or both a positive and a negative control.
[0060] By “corresponds to the presence and / or amount in a control sample” we include that the presence and / or amount is identical to that of a positive control sample; or closer to that of one or more positive control sample than to one or more negative control sample (or to predefined reference values representing the same). Preferably the presence and / or amount is within ±40% of that of the one or more control sample (or mean of the control samples), for example, within ±39%, ±38%, ±37%, ±36%, ±35%, ±34%, ±33%, ±32%, ±31%, ±30%, ±29%, ±28%, ±27%, ±26%, ±25%, ±24%, ±23%, ±22%, ±21%, ±20%, ±19%, ±18%, ±17%, ±16%, ±15%, ±14%, ±13%, ±12%, ±11%, ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.05% or within 0% of the one or more control sample (e.g., the positive control sample).
[0061] Alternatively or additionally, the difference in the presence or amount in the test sample is <5 standard deviation from the mean presence or amount in the control samples, for example, <4.5, <4, <3.5, <3, <2.5, <2, <1.5, <1.4, <1.3, <1.2, <1.1, <1, <0.9, <0.8, <0.7, 10 <0.6, <0.5, <0.4, <0.3, <0.2, <0.1 or 0 standard deviations from the from the mean presence or amount in the control samples.
[0062] Alternatively or additionally, by “corresponds to the presence and / or amount in a control sample” we include that the presence or amount in the test sample correlates with the amount in the control sample in a statistically significant manner. By “correlates with the amount in the control sample in a statistically significant manner” we mean or include that the presence or amount in the test sample correlates with the that of the control sample with a p-value of <0.05, for example, <0.04, <0.03, <0.02, <0.01, <0.005, <0.004, <0.003, 20 <0.002, <0.001, <0.0005 or <0.0001.
[0063] As exemplified in the accompanying Examples, the expression of 0X40 and / or OX40L in a tissue test sample may be indicative of HS in a subject.
[0064] In an alternative or additional embodiment, the presence and / or amount in the test sample of 0X40 and / or OX40L measured in step (b) may be compared against predetermined reference values representative of the measurements in step (d) i.e., reference negative and / or positive control values. As detailed above, the methods of the invention may also comprise measuring, in one or more negative or positive control samples, the presence and / or amount of 0X40 and / or OX40L measured in the test sample in step (b).
[0065] For example, one or more negative control samples may be from a subject who was not, at the time the sample was obtained, afflicted with HS. Thus, the negative control sample may be obtained from a healthy subject.
[0066] Likewise, one or more positive control samples may be from a subject who, at the time the sample was obtained, was afflicted with HS.
[0067] In an embodiment, the method is repeated using a test sample taken from the same subject at a different time period to the previous test sample(s) used.
[0068] In an embodiment, the method is repeated until HS is diagnosed or detected in the subject, or until a subject is selected for treatment, using the methods of the present invention and / or conventional clinical methods (i.e., until confirmation of the diagnosis is made, or until a subject is selected). Thus, steps (a) and (b) may be repeated using a sample from the same subject taken at a different time to the original sample tested (or the previous method repetition).
[0069] Thus, in an embodiment, the method is repeated using a test sample taken between 1 day to 150 weeks to the previous test sample(s) used, for 30 example, between 1 week to 100 weeks, 1 week to 90 weeks, 1 week to 80 weeks, 1 week to 70 weeks, 1 week to 60 weeks, 1 week to 50 weeks, 1 week to 40 weeks, 1 week to 30 weeks, 1 week to 20 weeks, 1 week to 10 weeks, 1 week to 9 weeks, 1 week to 8 weeks, 1 week to 7 weeks, 1 week to 6 weeks, 1 week to 5 weeks, 1 week to 4 weeks, 1 week to 3 weeks, or 1 week to 2 weeks.
[0070] Alternatively or additionally, the method may be repeated using a test sample taken every period from the group consisting of: 1 day, 2 days, 3 day, 4 days, 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, 30 weeks, 35 weeks, 40 weeks, 45 weeks, 50 weeks, 55 weeks, 60 weeks, 65 weeks, 70 weeks, 75 weeks, 80 weeks, 85 weeks, 90 weeks, 95 weeks, 100 weeks, 104, weeks, 105 5 weeks, 110 weeks, 115 weeks, 120 weeks, 125 weeks, 130 weeks, 135 weeks, 140 weeks, 145 weeks and 150 weeks.
[0071] Alternatively or additionally, the method is repeated at least once, for example, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 10 17 times, 18 times, 19 times, 20 times, 21 times, 22 times, 23, 24 times or 25 times. In an embodiment, step (b) comprises measuring the expression of the 0X40 and / or 0X40 ligand (OX40L) protein or polypeptide.
[0072] In one embodiment, step (a) comprises providing a tissue sample previously obtained from a subject to be tested and / or step (b) comprises measuring in the sample the presence and / or amount of the protein or polypeptide of 0X40 and / or OX40L. Thus, the presence and / or amount of 0X40 and / or OX40L may be determined at the protein level.
[0073] In an embodiment, step (b) and / or step (d) may be performed using one or more binding agents able to specifically detect 0X40 or OX40L (i.e. protein).
[0074] In an embodiment, step (b) and / or step (d) is performed using one or more binding agents able to detect the 0X40 and / or 0X40 ligand (OX40L) protein or polypeptide to be measured. As used herein, the term "binding agent able to detect 0X40 and / or OX40L" includes any agent capable of specifically binding to 0X40 or OX40L such that 0X40 and / or OX40L become detectable. By “specifically” or “selectively” binds, we include the meaning of a binding agent that exhibits appreciable affinity for a particular target (e.g. antigen) and, generally, does not exhibit significant cross-reactivity with other targets.
[0075] Suitable binding agents include antibodies, antibody derivatives, antibody fragments, and the like. Suitable agents for binding with a 0X40 and / or OX40L nucleic acid (e.g. a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids. For example, the nucleic acid agents may include oligonucleotides (labeled or nonlabeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.
[0076] In an embodiment, the binding agent is an antibody or a fragment thereof.
[0077] In an embodiment, the binding agent is a nucleic acid.
[0078] The presence, absence, and / or level of 0X40 and / or OX40L in a biological sample provided from a subject may be assessed by any of a wide variety of in vitro and in vivo techniques and methods, which enable 0X40 and / or OX40L within the sample to be detected and quantified. Non- limiting examples of such methods include analysing the sample using immunological methods for detection of proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods, enzyme linked immunosorbent assays (ELISAs), immunoblotting, Western blotting, Northern blotting, electron microscopy, mass spectrometry, immunoprecipitations, immunofluorescence, Southern hybridizations and the like. In one embodiment the presence, absence, and / or level 0X40 and / or OX40L in a sample can be assessed using a binding agent, such as an antibody (e.g., a radio-labeled, chromophore- labeled, fluorophore-labeled, or enzyme-labeled antibody), an antibody derivative (e.g. an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair (e.g. biotin-streptavidin)), or an antibody fragment (e.g., a single- chain antibody or an isolated antibody hypervariable domain) which binds specifically to and renders 0X40 and / or OX40L detectable in a sample.
[0079] By "labeled", with regard to an antibody, we include the meaning of direct labeling of the antibody by coupling (i.e., physically linking) a detectable substance to the antibody, as well the indirect labeling of the antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody, such that it can be detected with fluorescently labeled streptavidin.
[0080] In another embodiment, the presence, absence, and / or level of 0X40 and / or OX40L is assessed using a nucleic acid binding agent. For example, in one embodiment, the presence, absence, and / or level of 0X40 and / or OX40L is assessed using a nucleic acid probe.
[0081] By "probe" we include the meaning of any molecule that is capable of selectively binding to 0X40 and / or OX40L. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
[0082] Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to 0X40 and / or OX40L mRNA. The nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to 0X40 and / or OX40L genomic DNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. The skilled person can readily adapt known mRNA detection methods for use in detecting the level of 0X40 and / or OX40L mRNA.
[0083] In one embodiment of the invention, microarrays are used to detect 0X40 and / or OX40L expression. DNA microarrays provide one method for the simultaneous measurement of the expression levels of large numbers of genes. Each array consists of a reproducible pattern of capture probes attached to a solid support. Labeled RNA or DNA is hybridized to complementary probes on the array and then detected by laser scanning. Hybridization intensities for each probe on the array arc determined and converted to a quantitative value representing relative gene expression levels.
[0084] In an embodiment, the method further comprises or consists of administering to the subject an effective amount of an 0X40 modulator or an 0X40 ligand (OX40L) modulator.
[0085] In a particular embodiment, the 0X40 and / or OX40L modulator is an antibody, or fragment thereof.
[0086] In a particular embodiment, the methods of diagnosing or detecting HS, or the methods of selecting a subject having HS for treatment, can include a further step of detecting an additional marker of HS known in the art and / or determining one or more of Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), and Hurley Classification scores.
[0087] In another aspect, a method of assessing the efficacy of a treatment regimen for treating hidradenitis suppurativa (HS) in a subject is provided, the method comprising or consisting of the steps of: a) providing a treatment sample obtained from a subject following administration of a treatment regimen for HS; and b) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L).
[0088] In an embodiment, the method further comprises or consists of, prior to step a) a') providing a first sample obtained from said subject prior to administration of the treatment regimen to the subject, and optionally comparing the presence and / or amount in the first sample of the 0X40 and / or OX40L in step (a’) with the presence and / or amount in the treatment samples in step (a) wherein an increased presence and / or amount of the 0X40 and / or OX40L in the first sample relative to the treatment sample, is an indication that the treatment regimen is efficacious for treating HS in the subject. In an embodiment, the treatment regimen for HS comprises the standard of care for HS and / or administration of an 0X40 modulator or an OX40L modulator.
[0089] In an embodiment, the treatment regimen comprises administration of an 0X40 modulator or an 0X40 ligand (OX40L) modulator to the subject.
[0090] As used herein, the terms "efficacious" and "efficacy" refers to the likelihood that a treatment regimen will treat HS in a subject.
[0091] In an embodiment, the method further comprises confirming that the treatment regimen is efficacious and considered a viable treatment option by determining whether one or more of Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), and Hurley Classification scores is improved in the subject following treatment.
[0092] In an embodiment, the method is repeated using a treatment sample taken from the same subject at a different time period to the previous treatment sample(s) used.
[0093] In an embodiment, the method is repeated until efficacy is determined, using the methods of the present invention and / or conventional clinical methods. Thus, steps (a) and (b) may be repeated using a treatment sample from the same subject taken at a different time to the original treatment sample tested (or the previous method repetition).
[0094] Thus, in an embodiment, the method is repeated using a treatment sample taken between 1 day to 150 weeks to the previous test sample(s) used, for 30 example, between 1 week to 100 weeks, 1 week to 90 weeks, 1 week to 80 weeks, 1 week to 70 weeks, 1 week to 60 weeks, 1 week to 50 weeks, 1 week to 40 weeks, 1 week to 30 weeks, 1 week to 20 weeks, 1 week to 10 weeks, 1 week to 9 weeks, 1 week to 8 weeks, 1 week to 7 weeks, 1 week to 6 weeks, 1 week to 5 weeks, 1 week to 4 weeks, 1 week to 3 weeks, or 1 week to 2 weeks.
[0095] Alternatively or additionally, the method may be repeated using a treatment sample taken every period from the group consisting of: 1 day, 2 days, 3 day, 4 days, 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, 30 weeks, 35 weeks, 40 weeks, 45 weeks, 50 weeks, 55 weeks, 60 weeks, 65 weeks, 70 weeks, 75 weeks, 80 weeks, 85 weeks, 90 weeks, 95 weeks, 100 weeks, 104, weeks, 105 5 weeks, 110 weeks, 115 weeks, 120 weeks, 125 weeks, 130 weeks, 135 weeks, 140 weeks, 145 weeks and 150 weeks.
[0096] Alternatively or additionally, the method is repeated at least once, for example, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 10 17 times, 18 times, 19 times, 20 times, 21 times, 22 times, 23, 24 times or 25 times.
[0097] In an additional aspect, the use of one or more binding agents able to detect 0X40 and / or 0X40 ligand (OX40L) for diagnosing or detecting hi dradenitis suppurativa (HS) in a subject is provided.
[0098] Binding agents able to detect 0X40 and / or 0X40 ligand (OX40L) are known in the art and described herein. In an embodiment, the use is an in vitro use. In an embodiment, the use comprises measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L) as discussed above in relation to the methods of the invention.
[0099] Definitions
[0100] Listed below are definitions of various terms used to describe the embodiments disclosed herein. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
[0101] Unless otherwise defined, all scientific and technical terms used herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclature utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well-known and commonly used in the art.
[0102] As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a molecule” optionally includes a combination of two or more such molecules, and the like. The use of “or” herein is the inclusive or.
[0103] As used herein, the term “about” or “approximately” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. When referring to a measurable value such as an amount, a temporal duration, and the like, the term “about” or “approximately” is meant to encompass variations of ±20%, ±15%, or ±10%, including ±5%, ±1%, and ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. As used in this specification and claim(s), the term “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0104] As used herein, the term “consisting essentially of’ refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment.
[0105] The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.”
[0106] As used herein, the term “amino acid” includes alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine (Cys or C); glutamine (Gin or Q); glutamic acid (Glu or E); glycine (Gly or G); histidine (His or H); isoleucine (lie or I): leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Vai or V). Non-traditional amino acids are also within the scope of the disclosure and include norleucine, ornithine, norvaline, homoserine, and other amino acid residue analogues such as those described in Ellman et al. Meth. Enzymol. 202:301- 336 (1991). To generate such non-naturally occurring amino acid residues, the procedures of Noren et al. Science 244: 182 (1989) and Ellman et al., supra, can be used. Briefly, these procedures involve chemically activating a suppressor tRNA with a non-naturally occurring amino acid residue followed by in vitro transcription and translation of the RNA. Introduction of the non-traditional amino acid can also be achieved using peptide chemistries known in the art. As used herein, the term "polar amino acid" includes amino acids that have net zero charge, but have non-zero partial charges in different portions of their side chains (e.g., M, F, W, S, Y, N, Q, C). These amino acids can participate in hydrophobic interactions and electrostatic interactions. As used herein, the term "charged amino acid" includes amino acids that can have non-zero net charge on their side chains (e.g., R, K, H, E, D). These amino acids can participate in hydrophobic interactions and electrostatic interactions. As used herein, the term “conservative amino acid substitutions” refers to amino acid substitutions result from replacing one amino acid with another having similar structural and / or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine. Thus, a “conservative substitution” of a particular amino acid sequence refers to substitution of those amino acids that are not critical for polypeptide activity or substitution of amino acids with other amino acids having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitution of even critical amino acids does not reduce the activity of the peptide, (i.e. the ability of the peptide to penetrate the blood brain barrier (BBB)). Conservative substitution tables providing functionally similar amino acids are well known in the art. For example, the following six groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W). (See also Creighton, Proteins, W. H. Freeman and Company (1984), incorporated by reference in its entirety.) In some embodiments, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids can also be considered “conservative substitutions” if the change does not reduce the activity of the peptide. Insertions or deletions are typically in the range of about 1 to 5 amino acids. The choice of conservative amino acids may be selected based on the location of the amino acid to be substituted in the peptide, for example if the amino acid is on the exterior of the peptide and expose to solvents, or on the interior and not exposed to solvents.
[0107] In alternative embodiments, one can select the amino acid which will substitute an existing amino acid based on the location of the existing amino acid, i.e. its exposure to solvents (i.e. if the amino acid is exposed to solvents or is present on the outer surface of the peptide or polypeptide as compared to internally localized amino acids not exposed to solvents). Selection of such conservative amino acid substitutions are well known in the art, for example as disclosed in Dordo et al, J. Mol Biol, 1999, 217, 721-739 and Taylor et al., J. Theor. Biol. 119(1986);205-218 and S. French and B. Robson, J. Mol. Evol., 19(1983)171. Accordingly, one can select conservative amino acid substitutions suitable for amino acids on the exterior of a protein or peptide (i.e. amino acids exposed to a solvent), for example, but not limited to, the following substitutions can be used: substitution of Y with F, T with S or K, P with A, E with D or Q, N with D or G, R with K, G with N or A, T with S or K, D with N or E, I with L or V, F with Y, S with T or A, R with K, G with N or A, K with R, A with S, K or P.
[0108] In alternative embodiments, one can also select conservative amino acid substitutions encompassed suitable for amino acids on the interior of a protein or peptide, for example one can use suitable conservative substitutions for amino acids is on the interior of a protein or peptide (i.e. the amino acids are not exposed to a solvent), for example but not limited to, one can use the following conservative substitutions: where Y is substituted with F, T with A or S, I with L or V, W with Y, M with L, N with D, G with A, T with A or S, D with N, I with L or V, F with Y or L, S with A or T and A with S, G, T or V. In some embodiments, non-conservative amino acid substitutions are also encompassed within the term of variants.
[0109] As used herein, the term “administering,” refers to dispensing, delivering, or applying an active compound, i.e., an antibody or antigen-binding fragment thereof, according to the present disclosure, in a pharmaceutical formulation to a subject by any suitable route for delivery of the active compound to the subject. Examples of routes of administration include, but are not limited to, subcutaneous, intravenous, e.g., intravenous injection and intravenous infusion, e.g., via central venous access, intramuscular, oral, nasal, and pulmonary administration.
[0110] As used herein, the term “antibody” generally refers to immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM); however, immunoglobulin molecules consisting of only heavy chains (i.e., lacking light chains) are also encompassed within the definition of the term “antibody.” Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains, CHI , CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region comprises one domain (CL1). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementary determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Unless specifically indicated otherwise, the term “antibody,” as used herein, shall be understood to encompass complete antibody molecules as well as antigen-binding fragments thereof. The term “antigen-binding portion” or “antigen -binding fragment” of an antibody (or simply “antibody portion” or “antibody fragment”), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to a target antigen such as human OX40L or an epitope thereof.
[0111] As used herein, the term “antibody fragment” refers to a polypeptide that includes at least one immunoglobulin variable domain or immunoglobulin variable do-main sequence and which specifically binds a given antigen. An antibody fragment can comprise an antibody or a polypeptide comprising an antigen-binding domain of an antibody. In some embodiments, an antibody fragment can comprise a monoclonal antibody or a polypeptide comprising an antigen-binding domain of a monoclonal anti-body. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and an OX40L (L) chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two OX40L (L) chain variable regions. The term “antibody fragment” encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv, and domain antibodies (dAb) fragments (see, e.g. de Wildt et al., Eur J. Immunol., 1996; 26(3):629-39; which is incorporated by reference herein in its entirety)) as well as complete antibodies. An antibody can have the structural features of IgA, IgG, IgE, IgD, IgM (as well as subtypes and combinations thereof). Antibodies can be from any source, including mouse, rabbit, pig, rat, and primate (human and non-human primate) and primatized antibodies. Antibodies also include minibodies, humanized antibodies, chimeric antibodies, and the like.
[0112] As used herein, “antibody variable domain” refers to the portions of the OX40L and heavy chains of antibody molecules that include amino acid sequences of complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3), and framework regions (FRs). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the Light chain. According to the methods used in this disclosure, the amino acid positions assigned to CDRs and FRs may be defined according to Kabat (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991)) or according to IMGT nomenclature. As used herein, the term “antibody binding site” refers to a polypeptide or do-main that comprises one or more CDRs of an antibody and is capable of binding an antigen. For example, the polypeptide comprises a CDR3 (e.g., HCDR3). For example the polypeptide comprises CDRs 1 and 2 (e.g., HCDR1 and 2) or CDRs 1-3 of a variable domain of an antibody (e.g., HCDRsl-3). In one example, the antibody binding site is provided by a single variable domain (e.g., a VH or VL domain). In another example, the binding site comprises a VH / VL pair or two or more of such pairs.
[0113] 0X40 modulators are provided herein. In some embodiments, an “0X40 modulator” is an anti-OX40 monoclonal antibody or an 0X40 antagonistic antibody or an antibody that inhibits and reduces the number of activated OX40-expressing T cells. In some embodiments, an OX40L modulator is an anti-OX40L monoclonal antibody. In some embodiment, an OX40L modulator is an OX40L antagonistic antibody.
[0114] As used herein, the terms “antagonistic antibody” or “antagonist antibody” are used herein equivalently and include an antibody that is capable of inhibiting and / or neutralizing the biological signalling activity of, for example, 0X40 by blocking binding or substantially reducing binding of 0X40 to 0X40 ligand (OX40L) and thus inhibiting or reducing the signalling pathway triggered by 0X40 and / or inhibiting or reducing an OX40-mediated cell response like lymphocyte proliferation, cytokine expression, or lymphocyte survival.
[0115] As used herein, “0X40 antagonistic antibody” or “0X40 antagonist antibody” refers to an antibody or antigen-binding fragment thereof that is capable of inhibiting and / or neutralizing the biological signaling activity of 0X40, for example by blocking binding or substantially reducing binding of 0X40 to OX40L.
[0116] As used herein, “OX40L antagonistic antibody” or “OX40L antagonist antibody” refers to an antibody or antigen-binding fragment thereof that is capable of inhibiting and / or neutralizing the biological signaling activity of OX40L, for example by blocking binding or substantially reducing binding of 0X40 to OX40L.
[0117] As used herein, a “buffer” refers to a chemical agent that is able to absorb a certain quantity of acid or base without undergoing a strong variation in pH.
[0118] As used herein, the term “cell” is meant to refer to a cell that is in vitro, ex vivo, or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal. As used herein, the term “dose” refers to a specified amount or quantity of a medication taken or recommended to be taken at a particular time. As used herein, it is typically expressed in mg of the antibody or fragment thereof. It may alternatively be expressed in terms of mg / kg, accounting for patient bodyweight. A “daily dose” refers to the total dosage amount administered to an individual in a single 24-hour day.
[0119] As used herein, the term “dosage” refers to the administering of a specific amount, number, and frequency of doses over a specified period of time. Dosage implies duration. A “dosage regimen” is a treatment plan for administering a drug over a period of time.
[0120] As used herein, the terms “improve,” “improving” or “improvement” or grammatical variations thereof used in relation to behaviors refer to the ability to achieve a measurable increase in performance in relation to tasks used to test these behaviors in a subject, including humans or non-human animals.
[0121] As used herein, “injection” refers to a means of administration and encompasses for example IV and subcutaneous injections. An IV injection may be referred to as an infusion. It is also used herein to refer to an instance of administration wherein that administration is by injection, for example in the phrase “one or more induction phase injections”. Each injection will involve administration of a dose of antibody or fragment thereof.
[0122] As used herein, “injection device” refers to a device that is designed for carrying out injections, an injection including the steps of temporarily fluidically coupling the injection device to a person’s tissue, typically the subcutaneous tissue. An injection further includes administering an amount of aqueous drug into the tissue and decoupling or removing the injection device from the tissue. In some embodiments, an injection device can be an intravenous device or IV device, which is a type of injection device used when the target tissue is the blood within the circulatory system, e.g., the blood in a vein. A common, but non-limiting example of an injection device is a needle and syringe.
[0123] As used herein, “instructions” refers to a display of written, printed or graphic matter on the immediate container of an article, for example the written material displayed on a vial containing a pharmaceutically active agent, or details on the formulation and use of a product of interest included in a kit containing a formulation of interest. Instructions set forth the method of the treatment as contemplated to be administered or performed.
[0124] As used herein, the terms “isolated antibody” or “purified antibody” refers to an antibody that by virtue of its origin or source of derivation has one to four of the following: (1) is not associated with naturally associated components that accompany it in its native state, (2) is free or substantially free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. An isolated antibody is substantially free of other antibodies having different antigenic specificities.
[0125] As used herein, the term “formulation” as it relates to an antibody is meant to describe the antibody in combination with a pharmaceutically acceptable excipient comprising at least one buffer, at least one stabilizer, at least one surfactant, at least one chelating agent, and wherein the pH is as defined. As used herein, the term “formulation” may be used interchangeable with the term “composition.”
[0126] As used herein, “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler and Milstein, 1975, Nature 256:495, or may be made by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described in McCafferty et al., 1990, Nature 348:552-554, for example. As used herein, a “humanized” antibody refers to forms of non-human (e.g. murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non- human immunoglobulin. In exemplary embodiments, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. The humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. As used herein, the terms “level” and “levels” can be used interchangeably with the terms “concentration” and “concentrations.”
[0127] As use herein, the term “patient” or “subject” or “animal” or “host” refers to mammal. The subject may be a human, but can also be a mammal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, fowl, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
[0128] As used herein, the terms “peptide” or “polypeptide” are used interchangeably herein and refer to compounds consisting of from about 2 to about 90 amino acid residues, inclusive, wherein the amino group of one amino acid is linked to the carboxyl group of another amino acid by a peptide bond. A peptide can be, for example, derived or removed from a native protein by enzymatic or chemical cleavage, or can be prepared using conventional peptide synthesis techniques (e.g., solid phase synthesis) or molecular biology techniques (see Sambrook et al., MOLECULAR CLONING: LAB. MANUAL (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989)). A "peptide" can comprise any suitable L- and / or D-amino acid, for example, common a-amino acids (e.g., alanine, glycine, valine), non-a-amino acids (e.g., P-alanine, 4-aminobutyric acid, 6 aminocaproic acid, sarcosine, statine), and unusual amino acids (e.g., citrulline, homocitruline, homoserine, norleucine, norvaline, ornithine). The amino, carboxyl and / or other functional groups on a peptide can be free (e.g., unmodified) or protected with a suitable protecting group. Suitable protecting groups for amino and carboxyl groups, and means for adding or removing protecting groups are known in the art. See, e g., Green and Wuts, PROTECTING GROUPS IN ORGANIC SYNTHESIS (John Wiley and Sons, 1991). The functional groups of a peptide can also be derivatized (e.g., alkylated) using art-known methods.
[0129] As used herein, the term “pharmaceutical formulation” or “drug formulation” refers to a preparation which is in such form as to permit the biological activity of the active ingredients to be effective. “Pharmaceutical formulation” and the term “drug formulation” refer to a mixture or a structure in which different chemical substances, including the active drug, are combined to form a final medicinal product, such as a sterile product, a solution, a powder, an emulsion, a capsule, a tablet, a granule, a topical preparation, a non- conventional product such as semi-solid or sustained-release preparations, liquid, etc. Pharmaceutical formulation is prepared according to a specific procedure, a “formula.” The drug formed varies by the route of administration. As used herein, the term "formulation" as it relates to an antibody is meant to describe the antibody in combination with a pharmaceutically acceptable excipient comprising at least one buffer, at least one stabilizer, at least one surfactant, at least one chelating agent, and wherein the pH is as defined.
[0130] As used herein, the term “pharmaceutical formulation” is interchangeable with the term “pharmaceutical composition,” which further refers to the active agent in combination with a pharmaceutically acceptable carrier e.g., a carrier commonly used in the pharmaceutical industry. The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions or formulations, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0131] As used herein, the term “pharmaceutically acceptable excipients” (vehicles, additives) are those, which can safely be administered to a subject to provide an effective dose of the active ingredient employed. The term “excipient” or “carrier” as used herein refers to an inert substance, which is commonly used as a diluent, vehicle, preservative, binder or stabilizing agent for drugs. As used herein, the term “diluent” refers to a pharmaceutically acceptable (safe and non-toxic for administration to a human) solvent and is useful for the preparation of the aqueous formulations herein. Exemplary diluents include, but are not limited to, sterile water and bacteriostatic water for injection (BWFI).
[0132] As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the disclosure within or to the subject such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the disclosure, and not injurious to the subject. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
[0133] As used herein, the term “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the present disclosure, and are physiologically acceptable to the subject. In certain situations, supplementary active compounds may also be incorporated into a pharmaceutical formulation. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound disclosed herein. Other additional ingredients that may be included in a pharmaceutical formulation are known in the art and described, for example, in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
[0134] As used herein, the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional nontoxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used. The phrase “pharmaceutically acceptable salt” is not limited to a mono, or 1 : 1, salt. For example, “pharmaceutically acceptable salt” also includes bis-salts, such as a bishydrochloride salt. Lists of suitable salts are found in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
[0135] As used herein, the terms “portion,” “fragment,” “variant,” “derivative” and “analog,” when referring to a polypeptide of the present disclosure include any polypeptide that retains at least some biological activity referred to herein (e.g., antigen binding).
[0136] As used herein, the term “prevent” or “prevention” means no disorder or disease development if none had occurred, or no further disorder or disease development if there had already been development of the disorder or disease. Also considered is the ability of one to prevent some or all of the symptoms associated with the disorder or disease.
[0137] As used herein, the terms ‘treat,” “treatment,” “treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a condition associated with a disease or disorder. The term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition, disease or disorder. Treatment is generally “effective” if one or more symptoms or clinical markers are reduced. Alternatively, treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and / or decreased mortality, whether detectable or undetectable. The term “treatment” of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment). For treatment to be effective a complete cure is not contemplated. The method can in certain aspects include cure as well.
[0138] As used herein, the term “mg / kg” refers to the dose of a substance administered to an individual in milligrams per kilogram of body weight of the individual.
[0139] As used herein, “packaging” refers to how the components are organized and / or restrained into a unit fit for distribution and / or use. Packaging can include, e.g., boxes, bags, syringes, ampoules, vials, tubes, clamshell packaging, barriers and / or containers to maintain sterility, labeling, etc. As used herein, the term “recombinant antibody” is intended to include all antibodies that are prepared, expressed, created or isolated by recombinant means, for example antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial human antibody library, antibodies isolated from an animal (e.g. , a mouse) that is transgenic for human immunoglobulin genes or antibodies prepared, such recombinant human antibodies can be subjected to in vitro mutagenesis.
[0140] As used herein, “compounding” or “sterile compound” involves preparing medication in an environment free from bacteria, viruses, or any other potentially infectious microorganisms. Sterile compounding is used for preparations that will be administered either through an IV, injection, or directly into the eyes.
[0141] As used herein, the phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into a target tissue (e.g., the nervous system), such that it enters the animal's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
[0142] As used herein, the term “sequence identity,” “percent identity,” “percent homology,” or, for example, comprising a “sequence 80% identical to,” refer to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a “percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Vai, Leu, He, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gin, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
[0143] Calculations of sequence similarity or sequence identity between sequences (the terms are used interchangeably herein) can be performed as follows. To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences can be aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non- homologous sequences can be disregarded for comparison purposes). In certain embodiments, the length of a reference sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, 60%, or at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
[0144] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
[0145] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In some embodiments, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch, (1970, J. Mol. Biol. 48: 444-453) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another exemplary embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using an NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. Another exemplary set of parameters includes a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller (1989, Cabios, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
[0146] For instance, the peptide sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al., (1990, J. Mol. Biol, 215: 403-10). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to nucleic acid molecules of the disclosure. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the disclosure. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.
[0147] Definitions of common terms in cell biology and molecular biology can be found in “The Merck Manual of Diagnosis and Therapy,” 19th Edition, published by Merck Research Laboratories, 2006 (ISBN 0-911910-19-0); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); Benjamin Lewin, Genes X, published by Jones & Bartlett Publishing, 2009 (ISBN-10: 0763766321); Kendrew et al. (eds.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081- 569-8) and Current Protocols in Protein Sciences 2009, Wiley Intersciences, Coligan et al., eds.
[0148] Unless otherwise stated, standard procedures were used, as described, for example in Sambrook et al., Molecular Cloning: A Laboratory Manual (4 ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1995); or Methods in Enzymology: Guide to Molecular Cloning Techniques Vol.152, S. L. Berger and A. R. Kimmel Eds., Academic Press Inc., San Diego, USA (1987); Current Protocols in Protein Science (CPPS) (John E. Coligan, et al., ed., John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et al. ed., John Wiley and Sons, Inc.), and Culture of Animal Cells: A Manual of Basic Technique by R. Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes editors, Academic Press, 1st edition, 1998) which are all incorporated by reference herein in their entireties.
[0149] Other terms are defined herein within the description of the various embodiments of the disclosure.
[0150] Where aspects or embodiments of the disclosure are described in terms of a Markush group or other grouping of alternatives, the present disclosure encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group, but also the main group absent one or more of the group members. The present disclosure also envisages the explicit exclusion of one or more of any of the group members in the claims. The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the formulations, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. Moreover, due to biological functional equivalency considerations, some changes can be made in protein structure without affecting the biological or chemical action in kind or amount. These and other changes can be made to the disclosure of the detailed description. All such modifications are intended to be included within the scope of the appended claims.
[0151] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure. Any part of this disclosure may be read in combination with any other part of the disclosure, unless otherwise apparent from the context.
[0152] EXAMPLES
[0153] Example 1: Gene expression datasets & transcriptomic fingerprint
[0154] Public gene expression datasets (from NCBI GEO, website: ncbi.nlm.nih.gov / geo / ) were analyzed. The datasets used are set forth in FIG. 6. It was determined that the OX40L pathway was significantly enriched in dysregulated genes of HS (3 public gene expression datasets: GSE115099, GSE137141, GSE79149) (FIG. 1). 0X40 (TNFRSF4) level was significantly higher in HS based on multiple public gene expression datasets (FIG. 2). Details of 0X40 expression data are set forth at FIG. 3. 0X40 (TNFRSF4) was expressed in CD4 T cells of skin from HS patients (Public gene expression data GSE155850) (FIG. 4).
[0155] Transcriptomic fingerprint (TxFP) indication expansion analysis was performed by computing DGE overlap between the HS indication and anti-OX40L gene-sets and pval, odds-ratio and Jaccard index were computed. A nominal heat value was shown in the heatmap (FIG. 5). DGE in HS was defined as: abd(lfc)>0.5 & adj_pval<0.05. Upregulated gene signature in disease was matched with downregulated signature from anti-OX40L. Data was filtered for BH adjusted pval and only significant (padj<0.05) overlap signatures are reported here.
[0156] The GSE155176 study reported comparisons among patient cohorts (partial response, no response, pre-treatment) for adalimumab (anti-TNF treatment). Anti-OX40L downregulated genes showed significant overlap with genes upregulated in these various comparisons, aligning with an anti-OX40L strategy for the treatment of HS.
[0157] Example 2 : 0X40 & OX40L expression in HS vs. healthy skin
[0158] A highly significant increase was observed in themumbers of cells that expressed 0X40 or OX40L in HS patient skin lesions compared to skin from healthy donors in which such cells were hardly detectable.
[0159] Immunohistochemistry staining in skin samples
[0160] 0X40
[0161] • Mouse mAb anti -human 0X40 [ACT35] (cell signaling #98785 S)
[0162] • pH 9 pretreatment for 48 minutes, 1 hour incubation at room temperature with 6 pg / ml, anti-Mouse-HQ 16 minutes, anti-HQ-HRP 16 minutes, DAB
[0163] OX40L
[0164] • Rabbit mAb anti-human CD134 / OX40L [SP195] (Abeam Ab245756)
[0165] • pH 9 pretreatment for 64 minutes, 1 hour incubation at 37°C with 10 pg / ml, anti- Rb-HQ 1 hour, anti-HQ-HRP 32 minutes, DAB
[0166] Samples:
[0167] HS samples: n = 18 patients
[0168] Normal skin n = 10 patients Formalin-fixed paraffin-embedded skin samples were sectioned on a microtome at 5 pm. Sections were floated in deionized water, placed on glass slides, and allowed to dry. Immunostaining with anti-OX40 (clone ACT35, Cell Signaling Technology, 6pg / ml) and anti-OX40L (clone SP195, Abeam, lOpg / ml) primary antibody was performed on dewaxed slides using a Roche Ventana Ultra automate according to manufacturer’s instructions (Ventana Medical Systems, Inc, USA). All detection systems were manufactured by Ventana Medical System Inc. Primary antibody optimal concentration and IHC protocol were determined by individual pilot studies. Firstly, antigen retrieval procedure was applied with cell conditioning 1 (CC1) buffer (Tris / Borate / EDTA, pH8). Sections were then incubated with primary antibody, diluted in Signal Stain Antibody Diluent (Cell Signaling Technology) for 0X40 or IX Antibody Diluent / Block (Akoya Biosciences) for OX40L at 37°C (OX40L) or room temperature (0X40) for 1 hour before using ready -to- use Rabbit or Mouse HQ (Ventana Medical Systems, Inc, USA) and anti-HQ HRP multimer. Immunostaining was finalized using the universal 3,3 ’diaminobenzidine (DAB) chromogenic detection kit (Ventana Medical Systems, Inc, USA). A counterstaining step was also done with the hematoxylin II (Ventana Medical Systems, Inc, USA) and bluing reagent was applied (Ventana Medical Systems, Inc, USA). Stained slides were dehydrated, and cover slipped with cytoseal XYL (Richard-Allan scientific, USA).
[0169] OX40L expression levels were much lower in healthy skin vs. HS skin (FIG. 7). Similarly, 0X40 expression levels were much lower in healthy skin vs. HS skin (FIG. 8).
[0170] Image analysis was carried on using the HALO software (Indica Labs). Briefly, after tissue annotation and quality control, cell segmentation was performed based on nuclear staining, and 0X40- and OX40L-positive cells were counted. Cell densities are represented as number of cells per mm2of tissue. An increased density of 0X40+ and OX40L+ cells were observed in HS skin relative to healthy skin (FIG. 9).
[0171] References Cited
[0172] 1. Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nature Reviews. Disease Primers. 2020;6(l): 18.
[0173] 2. Zouboulis C.C., Nogueira da Costa A., Makrantonaki E., Hou X.X., Almansouri D., Dudley J.T., Edwards H., Readhead B., Balthasar O., Jemec G.B.E., et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2020;34:846-861. doi: 10.1111 / jdv.1614.
[0174] 3. Zouboulis VA, Zouboulis KC, Zouboulis CC. Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis . Pharmaceutics. 2021 Dec 26;14(1):44.
[0175] 4. Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen ARJV, et al. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis . JCI Insight. 2020;5(19).
[0176] 5. Lowe MM, Naik HB, Clancy S, Pauli M, Smith KM, Bi Y, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti -TNF-a therapy. JCI Insight. 2020;5(19).
[0177] 6. Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. JAAD Int. 2020;l(l):62-72.
[0178] 7. Frew JW, Grand D, Navrazhina K, Krueger JG. Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets? Exp Dermatol. 2020;29(5):509- 15
[0179] 8. Hambly R, et al., B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab. Br J Dermatol. 2023 Jan 23 ; 188(1): 52- 63.
Claims
WHAT IS CLAIMED:
1. A method of treating hi dradenitis suppurativa (HS) in a subject in need thereof, comprising administering to the subject an effective amount of an 0X40 modulator or an anti-OX40 ligand (OX40L) modulator.
2. The method of claim 1, wherein one or more of Dermatology Life Quality Index (DLQI), physician-assessed International HS Severity Score System (IHS4), and Hurley Classification scores are improved in the subject.
3. The method of claim 1 or 2, wherein 0X40 and / or OX40L expression level is reduced in the subject.
4. A method of treating hi dradenitis suppurativa (HS) in a subject in need thereof, comprising selecting a subject having an increased expression level of 0X40 relative to a control, and administering to the subject an effective amount of an 0X40 modulator or an anti-OX40 ligand (OX40L) modulator.
5. A method of diagnosing or detecting hi dradenitis suppurativa (HS) in a subject, the method comprising or consisting of the steps of: a) providing a sample obtained from a subject to be tested; and b) measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L), wherein the presence and / or amount in the sample of 0X40 and / or OX40L is indicative of HS in the subject.
6. The method according to Claim 5 further comprising or consisting of the steps of: c) providing one or more control samples; and d) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L), measured in step (b); wherein the subject is identified as having HS by comparing the presence and / or amount in the test sample of the 0X40 and / or 0X40 ligand (OX40L) in step (b) with the presence and / or amount in the control samples.
7. A method of selecting a subject having hidradenitis suppurativa (HS) for treatment, the method comprising or consisting of the steps of: a) providing a sample obtained from a subject to be tested; and b) measuring the presence and / or amount in the test sample of 0X40 and / or 0X40 ligand (OX40L), wherein the subject is selected as suitable for treatment based on the measurement in step b).
8. The method according to Claim 7 further comprising or consisting of the steps of: c) providing one or more control samples; and d) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L), measured in step (b); wherein the subject is selected for treatment by comparing the presence and / or amount in the test sample of the 0X40 and / or 0X40 ligand (OX40L) in step (b) with the presence and / or amount in the control samples.
9. The method according to Claim 6 or 8, wherein the control samples of step (c) are provided from a healthy individual (negative control) and / or from an individual with HS (positive control).
10. The method according to any one of Claims 5-9, wherein the method is repeated using a test sample taken from the same subject at a different time period to the previous test sample(s) used.
11. The method according to Claim 10, wherein the method is repeated using a test sample taken between 1 day to 150 weeks to the previous test sample(s) used, for 30 example, between 1 week to 100 weeks, 1 week to 90 weeks, 1 week to 80 weeks, 1 week to 70 weeks, 1 week to 60 weeks, 1 week to 50 weeks, 1 week to 40 weeks, 1 week to 30 weeks, 1 week to 20 weeks, 1 week to 10 weeks, 1 week to 9 weeks, 1 week to 8 weeks, 1 week to 7 weeks,1 week to 6 weeks, 1 week to 5 weeks, 1 week to 4 weeks, 1 week to 3 weeks, or 1 week to2 weeks.
12. The method according to Claim 10 or 11, wherein the method is repeated using a test sample taken every period from the group consisting of: 1 day, 2 days, 3 day, 4 days, 5 days, 6 days, 7 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, 30 weeks, 35 weeks, 40 weeks, 45 weeks, 50 weeks, 55 weeks, 60 weeks, 65 weeks, 70 weeks, 75 weeks, 80 weeks, 85 weeks, 90 weeks, 95 weeks, 100 weeks, 104, weeks, 105 5 weeks, 110 weeks, 115 weeks, 120 weeks, 125 weeks, 130 weeks, 135 weeks, 140 weeks, 145 weeks and 150 weeks.
13. The method according to any one of Claims 10-12, wherein the method is repeated at least once, for example, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, 15 times, 16 times, 10 17 times, 18 times, 19 times, 20 times, 21 times, 22 times, 23, 24 times or 25 times.
14. The method according to any one of Claims 5-13, wherein step (b) comprises measuring the expression of the 0X40 and / or 0X40 ligand (OX40L) protein or polypeptide.
15. The method according to Claim 14, wherein step (b) and / or step (d) is performed using one or more binding agents able to detect 0X40 or 0X40 ligand (OX40L) protein or polypeptide to be measured.
16. The method of any of Claims 5-15, further comprising administering to the subject an effective amount of an 0X40 modulator or an 0X40 ligand (OX40L) modulator.
17. A method of assessing the efficacy of a treatment regimen for treating hi dradenitis suppurativa (HS) in a subject, the method comprising or consisting of the steps of: a) providing a treatment sample obtained from a subject following administration of a treatment regimen for HS; and b) measuring the presence and / or amount in the control sample of the 0X40 and / or 0X40 ligand (OX40L),18. The method of Claim 17, further comprising, prior to step a) a') providing a first sample obtained from said subject prior to administration of the treatment regimen to the subject, andoptionally comparing the presence and / or amount of the 0X40 and / or 0X40 ligand (OX40L) from the first and treatment samples, wherein an increased presence and / or amount of the 0X40 and / or 0X40 ligand (OX40L) in the first sample, relative to the treatment sample, is an indication that the treatment regimen is efficacious for treating HS in the subject.
19. The method according to Claim 17 or 18, wherein the treatment regimen comprises administration of an 0X40 modulator or an 0X40 ligand (OX40L) modulator.
20. Use of one or more binding agents able to detect 0X40 and / or 0X40 ligand (OX40L) for diagnosing or detecting hi dradenitis suppurativa (HS) in a subject.
Citation Information
Patent Citations
Recombinant immunoglobin preparations
US4816567A
Methods of characterizing and treating hidradenitis suppurativa
US20200109453A1
Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
US20210188986A1
Bispecific molecules and methods of treatment using the same
WO2022079036A1
AU2020205839A1
Cited By
Treatment of atopic dermatitis
US12703754B2
